Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
The Lancet ( IF 98.4 ) Pub Date : 2017-08-01 , DOI: 10.1016/s1470-2045(17)30444-8 Annalisa Chiappella , Maurizio Martelli , Emanuele Angelucci , Ercole Brusamolino , Andrea Evangelista , Angelo Michele Carella , Caterina Stelitano , Giuseppe Rossi , Monica Balzarotti , Francesco Merli , Gianluca Gaidano , Vincenzo Pavone , Luigi Rigacci , Francesco Zaja , Alfonso D'Arco , Nicola Cascavilla , Eleonora Russo , Alessia Castellino , Manuel Gotti , Angela Giovanna Congiu , Maria Giuseppina Cabras , Alessandra Tucci , Claudio Agostinelli , Giovannino Ciccone , Stefano A Pileri , Umberto Vitolo
The Lancet ( IF 98.4 ) Pub Date : 2017-08-01 , DOI: 10.1016/s1470-2045(17)30444-8 Annalisa Chiappella , Maurizio Martelli , Emanuele Angelucci , Ercole Brusamolino , Andrea Evangelista , Angelo Michele Carella , Caterina Stelitano , Giuseppe Rossi , Monica Balzarotti , Francesco Merli , Gianluca Gaidano , Vincenzo Pavone , Luigi Rigacci , Francesco Zaja , Alfonso D'Arco , Nicola Cascavilla , Eleonora Russo , Alessia Castellino , Manuel Gotti , Angela Giovanna Congiu , Maria Giuseppina Cabras , Alessandra Tucci , Claudio Agostinelli , Giovannino Ciccone , Stefano A Pileri , Umberto Vitolo
|
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients.
中文翻译：
高危弥漫性大B细胞淋巴瘤（DLCL04）联合利妥昔单抗大剂量化疗加或不加大剂量化疗加自体干细胞移植：一项多中心，开放标签，随机，对照，3期研究的最终结果。
接受R-CHOP（利妥昔单抗，环磷酰胺，长春新碱，阿霉素和泼尼松）治疗的高危弥漫性大B细胞淋巴瘤（高危患者，国际预后指数[aa-IPI]评分为2或3）的年轻患者的预后为较差的。这项研究的目的是研究大剂量化学疗法和自体干细胞移植作为一线治疗的一部分在这些患者中强化治疗的可能益处。
更新日期：2017-08-10
中文翻译：
高危弥漫性大B细胞淋巴瘤（DLCL04）联合利妥昔单抗大剂量化疗加或不加大剂量化疗加自体干细胞移植：一项多中心，开放标签，随机，对照，3期研究的最终结果。
接受R-CHOP（利妥昔单抗，环磷酰胺，长春新碱，阿霉素和泼尼松）治疗的高危弥漫性大B细胞淋巴瘤（高危患者，国际预后指数[aa-IPI]评分为2或3）的年轻患者的预后为较差的。这项研究的目的是研究大剂量化学疗法和自体干细胞移植作为一线治疗的一部分在这些患者中强化治疗的可能益处。
京公网安备 11010802027423号